People in the News: Sinil Kim

Premium

Mirna Therapeutics has named Sinil Kim as its chief medical officer.

In this role, Kim will be responsible for the clinical development of Mirna’s phase I cancer drug MRX34, as well as other compounds in the firm’s pipeline, Mirna said.

Kim was most recently a senior director at Pfizer, serving as global clinical lead for two renal cancer drug programs. Before that, he was director of clinical oncology at Bristol-Myers Squibb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."